André de Villers
Gründer bei Millendo Therapeutics SAS
Profil
André de Villers was the founder of Theratechnologies, Inc. (founded in 1993) where he held the title of President from 1993 to 2004.
He is also the founder of Millendo Therapeutics SAS (founded in 2007) where he currently holds the title of Director.
Dr. de Villers's current jobs include being a Director at Panacis Medical, Inc., Jazz Pharmaceuticals II SASU, Montréal International, and President at CEMA, Inc.Dr. de Villers's former jobs include being the Chairman & Chief Executive Officer at CelMed BioSciences, Inc. from 2004 to 2006, and an Independent Director at TSO3, Inc. from 1998 to 2013.
He also held positions as Principal at SND Energy Ltd.
and Ecopia BioSciences, Inc.Dr. de Villers obtained his undergraduate degree from the University of Montréal in 1973.
Aktive Positionen von André de Villers
| Unternehmen | Position | Beginn |
|---|---|---|
Montréal International
 Montréal International Miscellaneous Commercial ServicesCommercial Services Montréal International attracts and promotes economic development of Greater Montreal. The company was founded in 1996 and is headquartered in Montréal, Canada. | Corporate Officer/Principal | - |
Millendo Therapeutics SAS
 Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Gründer | 08.09.2009 |
| Panacis Medical, Inc. | Direktor/Vorstandsmitglied | 08.09.2009 |
CEMA, Inc.
 CEMA, Inc. MiscellaneousMiscellaneous CEMA, Inc. operates as an investment holding company. The company is headquartered in Montreal, Canada. | Präsident | - |
Jazz Pharmaceuticals II SASU
 Jazz Pharmaceuticals II SASU Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals II SASU engages in the development of biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases. Its lead assets are pegcrisantaspase (Asparec), a PEGylated recombinant L-asparaginase from Erwinia chrysanthemi, and related intellectual property. The company was founded in 2008 and is headquartered in Ecully, France. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von André de Villers
| Unternehmen | Position | Ende |
|---|---|---|
| TSO3 INC. | Direktor/Vorstandsmitglied | 19.03.2013 |
CelMed BioSciences, Inc.
 CelMed BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Celmed BioSciences Inc. is a biopharmaceutical company. The company is engaged in developing breakthrough products to treat cancer. The company offers rational drug design and pharmacogenomic concepts to improve cancer patient care. Products of the company include Theralux and NB1011 which offers “Trojan horse solution' to treat cancer. The company is headquartered in Saint-Laurent, Canada. | Vorstandsvorsitzender | 28.11.2006 |
| THERATECHNOLOGIES INC. | Gründer | 01.06.2004 |
Ecopia BioSciences, Inc.
 Ecopia BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology | Corporate Officer/Principal | - |
| ░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von André de Villers
| University of Montréal | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| THERATECHNOLOGIES INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
CelMed BioSciences, Inc.
CelMed BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Celmed BioSciences Inc. is a biopharmaceutical company. The company is engaged in developing breakthrough products to treat cancer. The company offers rational drug design and pharmacogenomic concepts to improve cancer patient care. Products of the company include Theralux and NB1011 which offers “Trojan horse solution' to treat cancer. The company is headquartered in Saint-Laurent, Canada. | Health Technology |
TSO3, Inc.
 TSO3, Inc. Medical SpecialtiesHealth Technology TSO3, Inc. is a commercialization-stage medical device company, which engages in the provision of cutting-edge low temperature terminal sterilization technology. Its activities include sale, production, maintenance, research, development, and licensing of sterilization processes, related consumable supplies, and accessories for heat-sensitive medical devices. It operates through the Canada and Worldwide and United States geographical segments. The company was founded by Jocelyn Vézina and Simon Robitaille on June 10, 1998 and is headquartered in Quebec, Canada. | Health Technology |
Montréal International
Montréal International Miscellaneous Commercial ServicesCommercial Services Montréal International attracts and promotes economic development of Greater Montreal. The company was founded in 1996 and is headquartered in Montréal, Canada. | Commercial Services |
Millendo Therapeutics SAS
Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Health Technology |
| SND Energy Ltd. | Finance |
Ecopia BioSciences, Inc.
Ecopia BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology | Health Technology |
| Panacis Medical, Inc. | |
CEMA, Inc.
CEMA, Inc. MiscellaneousMiscellaneous CEMA, Inc. operates as an investment holding company. The company is headquartered in Montreal, Canada. | Miscellaneous |
Jazz Pharmaceuticals II SASU
Jazz Pharmaceuticals II SASU Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals II SASU engages in the development of biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases. Its lead assets are pegcrisantaspase (Asparec), a PEGylated recombinant L-asparaginase from Erwinia chrysanthemi, and related intellectual property. The company was founded in 2008 and is headquartered in Ecully, France. | Health Technology |
